drugset / Trial / NCT01672866

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

NCT01672866

Phase 2 Terminated 222 enrolled Gilead Sciences
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to evaluate whether SIM (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the clinical progression to cirrhosis in participants with NASH. It will consist of 2 phases: * Randomized Double-Blind Phase * Open-Label Phase (optional)

Timeline

Start
2012-12-05
Primary completion
2016-08-02
Completion
2016-12-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Simtuzumab Monoclonal antibody 75 mg Subcutaneous
Subject Simtuzumab Monoclonal antibody 125 mg Subcutaneous